ForeseeHome

What ForeseeHome does

ForeseeHome is a private medical device and remote monitoring service operated by Notal Vision, Inc. and headquartered in Manassas, Virginia, with founding origins in Tel Aviv, Israel in 2000. It provides an FDA-cleared, in-home monitoring device for patients with intermediate dry age-related macular degeneration (AMD), the leading cause of irreversible central vision loss in older adults. The device uses patented Preferential Hyperacuity Perimetry (PHP), a psychophysical test that presents brief dotted-line stimuli to detect metamorphopsia and scotoma within the central 14 degrees of the visual field, with results transmitted to the Notal Vision Monitoring Center where an algorithm compares them against the patient's personal baseline and AMD population norms to flag statistically significant changes.

The company sells no hardware outright; instead, it operates a monthly subscription monitoring service billed to Medicare, Medicare Advantage, commercial insurance, or directly to patients (up to $77.90/month for uninsured). Medicare Part B covers approximately 80% of the program cost for eligible patients. Distribution is entirely referral-based: optometrists, comprehensive ophthalmologists, and retina specialists enroll candidates through a HIPAA-compliant Eye Care Professional Portal, and the Monitoring Center handles benefits verification, device shipment, training, ongoing surveillance, and physician alerts. Clinical validation rests on 3.2 million real-world tests, the 10-year ALOFT Study of 2,123 patients, and IRIS Registry analysis of 162,902 eyes, with reported outcomes of 81% of monitored patients maintaining 20/40 or better vision at wet AMD detection versus 34% under standard methods.

Name

ForeseeHome

Legal name

Notal Vision, Inc.

Website

https://foreseehome.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

ForeseeHome, operated by Notal Vision, Inc., provides an FDA-cleared, Medicare-covered in-home PHP testing device and monthly monitoring subscription that helps eye care professionals detect conversion from intermediate dry AMD to wet AMD earlier in at-risk patients.

Ownership category

akta.pro rank

Product category

Remote Ophthalmic Monitoring

NAICS

Electronic and Precision Equipment Repair and Maintenance (8112)

SIC

Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

• AMD home monitoring
• Remote vision monitoring
• Ophthalmic diagnostic devices
• Retinal disease management
• Tele-ophthalmology services

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Monthly Monitoring Service Fee: ForeseeHome is provided as a monthly remote monitoring service. The device is loaned to patients, not sold. The Notal Vision Monitoring Center bills patients or their insurance a monthly monitoring service fee. Medicare Part B covers approximately 80% of the program cost.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

ForeseeHome is a remote home monitoring service for patients with intermediate dry age-related macular degeneration (AMD) that uses an FDA-cleared in-home device employing proprietary Preferential Hyperacuity Perimetry (PHP) technology to detect conversion to wet AMD earlier. The service is delivered through the Notal Vision Monitoring Center, which manages enrollment, device provisioning, daily test interpretation, and AI-driven alerts to referring eye care professionals when statistically significant vision changes occur.

Product overview

ForeseeHome is a comprehensive AMD monitoring platform consisting of the ForeseeHome AMD Monitoring Program, which combines an FDA-cleared in-home device utilizing Preferential Hyperacuity Perimetry (PHP) technology with the Notal Vision Monitoring Center service. The system enables early detection of wet AMD conversion through daily patient self-testing, with data transmitted to the Monitoring Center for analysis and alerting eye care professionals via the Eye Care Professional Portal when statistically significant changes are detected. Patients also access their results through a dedicated Patient Portal.

Differentiator

Problem solved

Functional benefit

Products and services

• ForeseeHome AMD Monitoring Program A prescription-only monthly remote monitoring program for patients with intermediate dry AMD that uses an in-home device with Preferential Hyperacuity Perimetry (PHP) testing to detect conversion to wet AMD earlier. The Notal Vision Monitoring Center manages enrollment, benefits verification, device shipment, training, daily test analysis, and alerting of the patient's eye doctor when significant changes occur.
• ForeseeHome Device An FDA-cleared, closed-viewer in-home device loaned to patients as part of the ForeseeHome monitoring program. It uses infrared sensors to ensure correct head positioning, then presents Preferential Hyperacuity Perimetry stimuli within the central 14 degrees of the visual field, testing 500 data points 3-5 times each, with a brief 2-minute daily test per eye.
• Notal Vision Monitoring Center A Medicare-credentialed remote ophthalmic monitoring service led by practicing ophthalmologists and supported by certified ophthalmic professionals that handles the entire patient journey including benefits verification, program enrollment, device training, ongoing daily monitoring, AI-driven alert analysis, and escalation to the referring eye doctor.

Quantifiable outcome

• 81% of patients maintained functional vision (20/40+) at wet AMD detection vs 34% with standard methods
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• MacuLogix: MacuLogix markets the AdaptDx, an at-home dark adaptation testing device for early AMD detection. It is the closest direct competitor to ForeseeHome's home-based AMD monitoring thesis, addressing the same patient population with an alternative psychophysical measurement approach.
• Heidelberg Engineering: Heidelberg Engineering manufactures OCT and confocal imaging systems widely used in AMD diagnosis and monitoring. Its SPECTRALIS platform is a direct alternative diagnostic technology for the same retina specialists who refer patients to ForeseeHome.
• CenterVue (now iCare): iCare (CenterVue) produces MAIA microperimetry and COMPASS fundus perimetry devices used in AMD and retinal disease diagnosis. These instruments are competitors to ForeseeHome's Preferential Hyperacuity Perimetry approach within the clinical perimetry category.
• Optos (Nikon): Optos, a Nikon subsidiary, manufactures ultra-widefield retinal imaging devices used in AMD detection and monitoring. It competes for share-of-mind and reimbursement dollars in the same AMD diagnostic workflow that ForeseeHome supports with between-visit home monitoring.

Broad incumbents

• Carl Zeiss Meditec: Carl Zeiss Meditec is a global leader in ophthalmic devices including the Humphrey Field Analyzer (HFA), the clinic gold standard for perimetry. It represents the incumbent in-office diagnostic that ForeseeHome's home-based PHP positioning competes against in the AMD and glaucoma workflow.
• Topcon Healthcare: Topcon provides a broad portfolio of ophthalmic diagnostic devices (OCT, fundus cameras, perimetry) deployed in eye care practices. It competes with ForeseeHome indirectly by enabling clinic-based AMD monitoring and screening workflows.
• Nidek: Nidek manufactures ophthalmic diagnostic equipment including perimeters and retinal imaging systems. It is an established incumbent offering clinic-based AMD-relevant diagnostics that serve the same referring eye-care professional customer base.
• Alcon: Alcon is a major global ophthalmology company with a broad portfolio of surgical, vision-care, and pharmaceutical products for AMD patient management. Although not a direct home-monitoring competitor, it is a key incumbent in the same AMD care continuum.
• Bausch + Lomb: Bausch + Lomb operates across pharmaceuticals, surgical, and vision-care segments of ophthalmology, including AMD-relevant therapeutics and diagnostics. As a broad incumbent, it competes for ophthalmology practice wallet share alongside ForeseeHome's monitoring offering.

Others

• Regeneron Pharmaceuticals: Regeneron markets Eylea, a leading anti-VEGF therapy for wet AMD. Although a treatment (not diagnostic) company, it sits in the same AMD care pathway — patients detected early with ForeseeHome are likely to receive Eylea, and changes in Eylea treatment protocols directly affect ForeseeHome's value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/foreseehome
• Facebookfacebook.com/ForeseeHome
• LinkedInlinkedin.com/company/notal-vision

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ForeseeHome